Option chain shows key data for Monopar Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Monopar Therapeutics.

Monopar Therapeutics (NASDAQ:MNPR) Stock, Option Chain

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

MNPR

MSTR

SEZL


Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy

3 Momentum Stocks Soaring Into 2025 and Beyond

movers image

News

Pre-Market Outlook

Movers

ADSE

ARBB

EONR

HCTI

IBRX

INDO

JFBR

JTAI

LENZ

LGVN

NWTN

PXDT

TARS

TCBP

TVGN

UPXI

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

AMZN

GTLB

NVDA

PANW

PLTR

RKLB

SERV

SOFI

TSLA

UBER

Equities were mixed this week; the Dow turned lower, but the S&amp;P and the NASDAQ finished higher. In fact, the NASDAQ hit a record high on Friday buoyed by the strong earnings report from Tesla.  
Overall,

MarketBeat Week in Review – 10/21- 10/25

Monopar Therapeutics Inc

Health Care

Press Releases

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

IPOs

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Financing

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Earnings

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Management

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Analyst Ratings

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Astria Therapeutics

aTyr Pharma

Candel Therapeutics

Cidara Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Emergent BioSolutions

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

ITeos Therapeutics

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

AVITA Medical

Solid Biosciences

Acelyrin

2seventy bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

HC Wainwright & Co.

Piper Sandler

Rodman & Renshaw

JonesTrading

Comments

Monopar Therapeutics

Monopar Therapeutics (MNPR) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell